To provide additional educational opportunities at AMCP Nexus 2018, the Academy of Managed Care Pharmacy (AMCP) also allows non-commercial, grant-supported satellite symposia. These learning activities are developed by medical education organizations and are an important part of the conference. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit. All satellite symposia will be held at the Orlando World Center Marriott. Any pre-registration taken for these activities is for planning purposes only and does not guarantee a seat. Seating is limited and provided on a first-come, first-served basis. We recommended an early arrival. For additional information about a specific symposium, please contact the program manager listed.
Getting to the Heart of Long-Anticipated CVOTs: Implications for Lipid Management
Monday, October 22, 2018 | 11:00 am - 12:30 pm
Provided by Prime Education, LLC.
Supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
Continuing education credit available for pharmacists, physicians and nurses.
Program Description
Cholesterol management for the prevention of cardiovascular events and premature deaths presents ongoing and evolving challenges. During this program, three leading lipidology and managed care experts will address the methods by which providers can accurately risk stratify patients and define the characteristics of patient groups that should receive particular lipid lowering therapies, as well as debate the implications of recently released cardiovascular outcomes data for better management of high-risk patients. The faculty will engage the audience and discuss recently completed CVOTs on PCSK9, including the interpretation of key results, clinical significance, discussing the differences in study design, patient population in the context of previous trials conducted in lipid-lowering therapies.
Top 3 Reasons to Attend:
1. Learn what the results of long-term cardiovascular outcomes mean for you
2. Mitigate costs through timely and appropriate treatment selection
3. Ask the experts your most pressing questions
Program Manager
Tammy Gonzalez
PRIME Education, LLC
t.gonzalez@primeinc.org
954- 718-6055
No Fee Registration: Click here.
Rheumatoid Arthritis Management Strategies: New Insights for Managed Care
Monday, October 22, 2018 | 11:00 am - 12:30 pm
Jointly provided by Impact Education, LLC and Postgraduate Institute for Medicine.
Supported by an independent educational grant from AbbVie, Inc.
Continuing education credit available for pharmacists and physicians.
Program Description
There are 2.5 times as many women as men with rheumatoid arthritis (RA) and the onset usually occurs in middle-age; however, RA can occur in young adults as well. A cure for RA remains elusive, but effective drugs are available to manage symptoms and minimize disease progression. In addition to medications, regular performance of self-management techniques, including physical activity, are known to reduce pain and disability. RA treatment goals include controlling pain and inflammation, achieving the lowest disease activity, and ultimately, remission.
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102
No Fee Registration: Click here.
The Specialty Pharmacy Review Board™ – Examining Emerging Biologics for Difficult-to-treat or Severe Asthma
Monday, October 22, 2018 | 6:00 pm – 8:00 pm
Jointly provided by Impact Education, LLC and Postgraduate Institute for Medicine.
Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Continuing education credit available for pharmacists and physicians.
Program Description
Managed care professionals are in a unique position to guide and positively influence the practice of network providers in terms of individualized asthma management; this represents a critical step towards the optimization of patient care and treatment outcomes. However, among many MCOs, little is known about the characteristics and asthma burden of difficult-to-treat or severe asthma. With the development and introduction of new therapies directed at patients with severe or difficult-to-treat asthma, it is important to better understand the prevalence and characteristics of such patients in a general asthma population who may benefit from the newly introduced and emerging treatments.
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102
No Fee Registration: Click here.
More than a Skin-Deep Look at Psoriasis' Costs and Outcomes (with a Few Surprises)
Monday, October 22, 2018 | 6:00 pm – 8:00 pm
Provided by Prime Education, LLC
Supported by an independent educational grant from AbbVie, Inc.
Continuing education credit available for pharmacists, physicians and nurses.
Program Description
Significant comorbidities, loss of productivity, and escalating pharmacy costs are driving up the economic burden of psoriasis. Only by applying the latest data to optimize treatment selection and timing can organizations effectively contain these costs. This symposium features a panel of experts in psoriasis and managed care who will interpret new data on the safety, efficacy, and utility of new and emerging therapies for psoriasis. They will also address biologics' efficacy in psoriasis compared with other inflammatory diseases.
Top 3 Reasons to Attend:
1. Get cutting-edge evidence with major implications for psoriasis care
2. Ask the experts your most pressing questions
3. Mitigate costs through timely and appropriate treatment selection
Program Manager
Tammy Gonzalez
PRIME Education, LLC
t.gonzalez@primeinc.org
954- 718-6055
No Fee Registration: Click here.
Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC: A Primer for Managed Care Pharmacy
Tuesday, October 23, 2018 | 6:00 am – 8:00 am
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Supported by an independent educational grant from AstraZeneca. Continuing education credit available for pharmacists.
Program Description
Recent data have expanded treatment options for unresectable stage III non-small-cell lung cancer (NSCLC). With the evolution in the use of immunotherapy for stage III NSCLC, managed care pharmacy professionals will benefit from expert perspectives on these data and how they should be integrated into care plans for their patients with early-stage disease.
Participants in this interactive, CE-certified symposium can expect to achieve an increased awareness and competency in applying this new treatment paradigm into practice. Both oncology and pharmacy experts will review the underlying rationale and the latest clinical data for immune checkpoint inhibitor therapy for patients with unresectable stage III NSCLC. The program faculty will also provide practical guidance on the following:
• Integrating cancer immunotherapies into stage III treatment plans
• Identification of patients most likely to benefit from immunotherapy
• Identification and optimal management of immune-related adverse events
• Patient education, consultation, and collaboration strategies
Attendees will have the opportunity to interact with the expert panelists during open discussion built into the agenda and throughout the event they will have the ability to text in questions and case challenges to the program faculty.
Program Manager
Kristi Beck
Clinical Care Options, LLC
Meetings@clinicaloptions.com
No Fee Registration: Click here.
Biosimilars in Practice: A Guide for Managed Care Professionals
Tuesday, October 23, 2018 | 6:30 pm – 8:30 pm
Jointly provided by Impact Education, LLC and Postgraduate Institute for Medicine. Supported by an independent educational grant from Amgen. Continuing education credit available for pharmacists and physicians.
Program Description
Biologic drugs have revolutionized the treatment of many acute and chronic conditions. By 2020, it is anticipated that several “innovator” or “reference” biologics will lose patent protection. Consequently, interest in biosimilar or biologic products highly similar to an FDA-approved biologic product (with no clinically meaningful differences in terms of safety and effectiveness from the reference product) is intensifying.
Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812, extension 102
No Fee Registration: Click here.
An American Journal of Managed Care® Symposium: The Era of PARP Inhibition in Cancer Management - Patient Selection and Deciding When to Use in Treatment
Tuesday, October 23, 2018 | 6:30 pm – 8:30 pm
Provided by Pharmacy Times Continuing Education™.
Supported by an independent educational grant from AstraZeneca. Continuing education credit available for pharmacists.
Program Description
Poly (ADP-ribose) polymerase (PARP) inhibitors are small molecules that block the PARP enzyme, which is instrumental in binding single-strand DNA damage and initiating repair. The first PARP inhibitor, olaparib, is currently indicated for the treatment of BRCA-mutated ovarian cancer and breast cancer, treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy. Two additional PARP inhibitors, niraparib, and most recently, rucaparib have been approved. Other BRCA-mutated cancers such as melanoma and pancreatic cancer have shown responses to PARP inhibitors. These agents differ in dosing, metabolism, and toxicities. As the options for cancer management grow, it is essential for managed care professionals to understand the role of new and emerging therapies to offer patients the most safe and efficacious treatment, while controlling costs. This symposium will highlight the role of the managed care professional in the identification of patients who may benefit from treatment using PARP inhibitors while managing the cost of therapy.
Project Manager
Nicole Grassano
Pharmacy Times Continuing Education™
ngrassano@pharmacytimes.com
No Fee Registration: Click here.
An American Journal of Managed Care® Symposium: Impact of von Willebrand Disease on Costs and Patient Outcomes – Featuring a Patient Perspective
Wednesday, October 24, 2018 | 6:00 am – 7:45 am
Provided by Pharmacy Times Continuing Education™.
Supported by an independent educational grant from CSL Behring. Continuing education credit available for pharmacists.
Von Willebrand disease is the most prevalent bleeding disorder and affects up to 1% of the population worldwide. This live symposium will differentiate between current and emerging von Willebrand factors and delve into managed care and specialty pharmacy approaches to manage both the disease and its costs. Integrated with this discussion will be the addition of a patient perspective, which will provide insight on the experience of being diagnosed, starting new therapies, and obtaining access to these medications.
Project Manager
Nicole Grassano
Pharmacy Times Continuing Education™
ngrassano@pharmacytimes.com
No Fee Registration: Click here.
Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings - Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology
Wednesday, October 24, 2018 | 6:00 am – 7:45 am
Jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
Supported by independent educational grants from Bristol-Myers Squibb and Merck & Co., Inc. Continuing education credit available for pharmacists, physicians and nurses.
Program Description
The emergence of immune checkpoint inhibitors and therapeutic strategies incorporating immuno-oncology (IO) approaches has been a game-changer in cancer treatment. Adoption of IO is no longer a question of “if,” but “how.” How to determine which patients with cancer are the best candidates for immunotherapies, which agents or combinations to use when and for how long, and how to balance the benefits with the risks (including immune-related and other overlapping/non-overlapping adverse effects) and costs of these therapies in the context of a value-based care model are questions that must be addressed in all cancer care delivery settings, including managed care. Considerable efforts have been made to identify useful biomarkers that can help to refine patient selection. There are also concerns that typical models used to assess the value of cancer treatments are ill-designed for the era of IO and don’t take into account the unique characteristics of immunotherapies. It is important to consider the latest evidence, evolving research, and real-world examples of innovation that could inform how to best integrate IO in managed care settings. All these topics will be addressed by oncology and managed care experts during this CME/CE/CPE-certified, interactive, practically-oriented live educational symposium.
Program Manager
Krystal Scharon
PVI, PeerView Institute for Medical Education
krystal.scharon@peerview.com
1-877-833-6141
No Fee Registration: Click here.
Tailoring Treatment of EGFR¬-Mutated NSCLC: Pharmacy Perspectives to Improve Patient Care
Wednesday, October 24, 2018 | 6:00 pm – 8:00 pm
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC. Supported by an independent educational grant from AstraZeneca. Continuing education credit available for pharmacists.
Program Description
New data have affected the optimal clinical application of EGFR-targeted therapies in the management of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) and EGFR-sensitizing mutations. With the availability of multiple EGFR TKIs, managed care pharmacy professionals will benefit from practical guidance how best to integrate these agents into care plans for their patients, especially clinical challenges and questions regarding the optimal sequencing of EGFR TKI therapy.
Both oncology and pharmacy experts will provide their perspectives on the role of EGFR-targeted therapies in the management of patients with advanced EGFR-mutated NSCLC, including:
• Importance of molecular testing
• Comparative efficacy of EGFR TKIs as related to the landscape of EGFR mutations
• EGFR TKI pharmacology, including comparison of toxicities and CNS activity
• Insights into the latest first-line and second-line clinical data on available EGFR TKIs
• Improving patient outcomes and providing cost-effective care in EGFR-mutated NSCLC
Attendees will have the opportunity to interact with the expert panelists during open discussion built into the agenda and throughout the event they will have the ability to text in questions and case challenges to the program faculty.
Program Manager
Kristi Beck
Clinical Care Options, LLC
Meetings@clinicaloptions.com
No Fee Registration: Click here.
An American Journal of Managed Care Symposium®: A Physician and Payer Perspective on ALS Advances
Wednesday, October 24, 2018 | 6:00 pm – 8:00 pm
Provided by Pharmacy Times Continuing Education™.
Supported by an independent educational grant from Mitsubishi Tanabe Pharma America, Inc.
Continuing education credit available for pharmacists.
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a neuromuscular disease where most patients die within 3 to 5 years of the onset of symptoms. Recognizing early symptoms and staying up-to-date on advances in pharmacotherapy will help prolong the quality of life for these patients. This symposium will highlight the role of healthcare professionals in making informed decisions on therapies that will improve patient outcomes and slow the disease progression while minimizing costs.
Project Manager
Nicole Grassano
Pharmacy Times Continuing Education™
ngrassano@pharmacytimes.com
No Fee Registration: Click here.
An American Journal of Managed Care Symposium®: PCSK9 Inhibitor Data Updates and the Implications to Population Health
Thursday, October 25, 2018 | 6:00 am – 7:45 am
Provided by Pharmacy Times Continuing Education™.
Supported by an independent educational grant from Amgen.
Continuing education credit available for pharmacists.
Program Description
In the United States, cardiovascular disease (CVD) is the leading cause of death among adults; specifically, patients with familial hypercholesterolemia (FH) have an even greater risk of developing CVD. PCSK9 inhibitors have been used in the management of FH, but this class of medications has limited access due to restrictions imposed by payers. New data from various trials are critical for managed care professionals to understand and to be able to devise informed strategies for optimal patient care.
Project Manager
Nicole Grassano
Pharmacy Times Continuing Education™
ngrassano@pharmacytimes.com
No Fee Registration: Click here.